Localization Of Metastasis Within The Sentinel Lymph Node Biopsies: A Predictor Of Additional Axillary Spread Of Breast Cancer? [localização Da Metástase No Interior Dos Linfonodos Sentinelas: Um Preditor De Disseminação Adicional Axilar Em Câncer De Mama?]

Purpose: To explore the relationship between morphological characteristics and histologic localization of metastasis within sentinel lymph nodes (SLN) and axillary spread in women with breast cancer. Methods: We selected 119 patients with positive SLN submitted to complete axillary lymph node dissection from July 2002 to March 2007. We retrieved the age of patients and the primary tumor size. In the primary tumor, we evaluated histologic and nuclear grade, and peritumoral vascular invasion (PVI). In SLNs we evaluated the size of metastasis, their localization in the lymph node, number of foci, number of involved lymph nodes, and extranodal extension. Results: Fifty-one (42.8%) patients had confirmed additional metastasis in non-sentinel lymph nodes (NLSN). High histologic grade, PVI, intraparenchymatous metastasis, extranodal neoplastic extension and size of metastasis were associated with positive NLSN. SLN metastasis affecting the capsule were associated to low risk incidence of additional metastasis. After multivariate analysis, PVI and metastasis size in the SLN remained as the most important risk factors for additional metastasis. Conclusions: The risk of additional involvement of NSLN is higher in patients with PVI and it increases progressively according the histologic localization in the lymph node, from capsule, where the afferent lymphatic channel arrives, to the opposite side of capsule promoting the extranodal extension. Size of metastasis greater than 6.0 mm presents higher risk of additional lymph node metastasis.3511483489Giuliano, A.E., Mapping a pathway for axillary staging: A personal perspective on the current status of sentinel lymph node dissection for breast cancer (1999) Arch Surg., 134 (2), pp. 195-199Ernst, M.F., Voogd, A.C., Balder, W., Klinkenbijl, J.H., Roukema, J.A., Early and late morbidity associated with axillary levels I-III dissection in breast cancer (2002) J Surg Oncol., 79 (3), pp. 151-155Edge, S.B., Niland, J.C., Bookman, M.A., Theriault, R.L., Ottesen, R., Lepisto, E., Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers (2003) J Natl Cancer Inst., 95 (20), pp. 1514-1521Noguchi, M., Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients (2001) J Surg Oncol., 76 (2), pp. 144-156Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer (2003) N Engl J Med., 349 (6), pp. 546-553Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer (2002) N Engl J Med., 347 (16), pp. 1233-1241Giuliano, A.E., Hunt, K.K., Ballman, K.V., Beitsch, P.D., Whitworth, P.W., Blumencranz, P.W., Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial (2011) JAMA., 305 (6), pp. 569-575Giuliano, A.E., Kirgan, D.M., Guenther, J.M., Morton, D.L., Lymphatic mapping and sentinel lymphadenectomy for breast cancer (1994) Ann Surg., 220 (3), pp. 391-401Czerniecki, B.J., Scheff, A.M., Callans, L.S., Spitz, F.R., Bedrosian, I., Conant, E.F., Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma (1999) Cancer., 85 (5), pp. 1098-1103Albertini, J.J., Lyman, G.H., Cox, C., Yeatman, T., Balducci, L., Ku, N., Lymphatic mapping and sentinel node biopsy in the patient with breast cancer (1996) JAMA., 276 (22), pp. 1818-1822Veronesi, U., Paganelli, G., Galimberti, V., Viale, G., Zurrida, S., Bedoni, M., Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes (1997) Lancet., 349 (9069), pp. 1864-1867Kamath, V.J., Giuliano, R., Dauway, E.L., Cantor, A., Berman, C., Ku, N.N., Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: A study to evaluate the need for complete axillary lymph node dissection (2001) Arch Surg., 136 (6), pp. 688-692Veronesi, U., Paganelli, G., Viale, G., Galimberti, V., Luini, A., Zurrida, S., Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series (1999) J Natl Cancer Inst., 91 (4), pp. 368-373Van Zee, K.J., Manasseh, D.M., Bevilacqua, J.L., Boolbol, S.K., Fey, J.V., Tan, L.K., A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy (2003) Ann Surg Oncol., 10 (10), pp. 1140-1151Cserni, G., Boross, G., Maráz, R., Leidenius, M.H., Meretoja, T.J., Heikkila, P.S., Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer (2012) Surg Oncol., 21 (2), pp. 59-65(2010) AJCC Cancer Staging Manual, , American Joint Committee on Cancer. 7th ed. New York: Springer VerlagElston, C.W., Ellis, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up (1991) Histopathology., 19 (5), pp. 403-410Carcoforo, P., Maestroni, U., Querzoli, P., Lanzara, S., Maravegias, K., Feggi, L., Primary breast cancer features can predict additional lymph node involvement in patients with sentinel node micrometastases (2006) World J Surg., 30 (9), pp. 1653-1657Fougo, J.L., Afonso, M., Senhorães Senra, F., Dias, T., Leal, C., Araújo, C., Predictive factors for non-sentinel lymph node involvement in breast cancer patients with a positive sentinel node: Should we consider sentinel node-related factors? (2009) Clin Transl Oncol., 11 (3), pp. 165-171Hwang, R.F., Krishnamurthy, S., Hunt, K.K., Mirza, N., Ames, F.C., Feig, B., Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer (2003) Ann Surg Oncol., 10 (3), pp. 248-254Mustać, E., Matusan-Ilijas, K., Marijić, B., Smokvina, M., Jonjić, N., Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy (2010) Int J Surg Pathol., 18 (1), pp. 36-41Viale, G., Maiorano, E., Pruneri, G., Mastropasqua, M.G., Valentini, S., Galimberti, V., Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy (2005) Ann Surg., 241 (2), pp. 319-325Bolster, M.J., Peer, P.G., Bult, P., Thunnissen, F.B., Schapers, R.F., Meijer, J.W., Risk factors for non-sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study (2007) Ann Surg Oncol., 14 (1), pp. 181-189Bernardi, S., Bertozzi, S., Londero, A.P., Giacomuzzi, F., Angione, V., Dri, C., Nine years of experience with the sentinel lymph node biopsy in a single Italian center: A retrospective analysis of 1,050 cases (2012) World J Surg., 36 (4), pp. 714-722Abdessalam, S.F., Zervos, E.E., Prasad, M., Farrar, W.B., Yee, L.D., Walker, M.J., Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer (2001) Am J Surg., 182 (4), pp. 316-320Chu, K.U., Turner, R.R., Hansen, N.M., Brennan, M.B., Bilchik, A., Giuliano, A.E., Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? (1999) Ann Surg., 229 (4), pp. 536-541Fleming, F.J., Kavanagh, D., Crotty, T.B., Quinn, C.M., McDermott, E.W., O'Higgins, N., Factors affecting metastases to non-sentinel lymph nodes in breast cancer (2004) J Clin Pathol., 57 (1), pp. 73-76Joseph, K.A., El-Tamer, M., Komenaka, I., Troxel, A., Ditkoff, B.A., Schnabel, F., Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis (2004) Arch Surg., 139 (6), pp. 648-651Wong, S.L., Edwards, M.J., Chao, C., Tuttle, T.M., Noyes, R.D., Woo, C., Predicting the status of the nonsentinel axillary nodes: A multicenter study (2001) Arch Surg., 136 (5), pp. 563-568Zavagno, G., De Salvo, G.L., Bozza, F., Scalco, G., Marconato, R., Valletta, S., Number of metastatic sentinel nodes as predictor of axillary involvement in patients with breast cancer (2004) Breast Cancer Res Treat., 86 (2), pp. 171-179Meretoja, T.J., Vironen, J.H., Heikkilä, P.S., Leidenius, M.H., Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection (2010) J Surg Oncol., 102 (3), pp. 215-219Ozcinar, B., Muslumanoglu, M., Igci, A., Gurdal, S.O., Yavuz, E., Kecer, M., Clinical importance of micrometastasis in sentinel lymph nodes (2011) Breast., 20 (1), pp. 31-33Turner, R.R., Chu, K.U., Qi, K., Botnick, L.E., Hansen, N.M., Glass, E.C., Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node (2000) Cancer., 89 (3), pp. 574-581Sachdev, U., Murphy, K., Derzie, A., Jaffer, S., Bleiweiss, I.J., Brower, S., Predictors of nonsentinel lymph node metastasis in breast cancer patients (2002) Am J Surg., 183 (3), pp. 213-217Reynolds, C., Mick, R., Donohue, J.H., Grant, C.S., Farley, D.R., Callans, L.S., Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer? (1999) J Clin Oncol., 17 (6), pp. 1720-1726Diaz, L.K., Hunt, K., Ames, F., Meric, F., Kuerer, H., Babiera, G., Histologic localization of sentinel lymph node metastases in breast cancer (2003) Am J Surg Pathol., 27 (3), pp. 385-389Paish, E.C., Green, A.R., Rakha, E.A., McMillan, R.D., Maddison, J.R., Ellis, I.O., Three-dimensional reconstruction of sentinel lymph nodes with metastatic breast cancer indicates three distinct patterns of tumour growth (2009) J Clin Pathol., 62 (7), pp. 617-62

Advancing tools to promote health equity across European Union regions : The EURO-HEALTHY project

Population health measurements are recognised as appropriate tools to support public health monitoring. Yet, there is still a lack of tools that offer a basis for policy appraisal and for foreseeing impacts on health equity. In the context of persistent regional inequalities, it is critical to ascertain which regions are performing best, which factors might shape future health outcomes and where there is room for improvement. Under the EURO-HEALTHY project, tools combining the technical elements of multi-criteria value models and the social elements of participatory processes were developed to measure health in multiple dimensions and to inform policies. The flagship tool is the Population Health Index (PHI), a multidimensional measure that evaluates health from the lens of equity in health determinants and health outcomes, further divided into sub-indices. Foresight tools for policy analysis were also developed, namely: (1) scenarios of future patterns of population health in Europe in 2030, combining group elicitation with the Extreme-World method and (2) a multi-criteria evaluation framework informing policy appraisal (case study of Lisbon). Finally, a WebGIS was built to map and communicate the results to wider audiences. The Population Health Index was applied to all European Union (EU) regions, indicating which regions are lagging behind and where investments are most needed to close the health gap. Three scenarios for 2030 were produced - (1) the 'Failing Europe' scenario (worst case/increasing inequalities), (2) the 'Sustainable Prosperity' scenario (best case/decreasing inequalities) and (3) the 'Being Stuck' scenario (the EU and Member States maintain the status quo). Finally, the policy appraisal exercise conducted in Lisbon illustrates which policies have higher potential to improve health and how their feasibility can change according to different scenarios. The article makes a theoretical and practical contribution to the field of population health. Theoretically, it contributes to the conceptualisation of health in a broader sense by advancing a model able to integrate multiple aspects of health, including health outcomes and multisectoral determinants. Empirically, the model and tools are closely tied to what is measurable when using the EU context but offering opportunities to be upscaled to other settings